Etanercept

Drug Profile

Etanercept

Alternative Names: Enbrel; p75TNFR-Ig; rhu TNFR-Fc; Soluble tumour necrosis factor receptor p75 Fc IgG1 fusion protein; TNF receptor fusion protein; TNFR-Fc-p75; TNR-001

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Pantec Biosolutions; Pfizer; University of Leeds
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Graft-versus-host disease
  • Phase II Discoid lupus erythematosus
  • No development reported Metabolic syndrome
  • Discontinued Adult-onset Still's disease; Asthma; Behcet's syndrome; Cachexia; Heart failure; Myasthenia gravis; Pulmonary fibrosis; Septic shock; Transplant rejection; Wegener's granulomatosis

Most Recent Events

  • 14 Feb 2017 Amgen has patent protection for etanercept in USA (Amgen 10-K, February 2017)
  • 28 Nov 2016 Phase-I clinical trials in Plaque psoriasis in Switzerland (Topical) (NCT02999776)
  • 11 Nov 2016 Efficacy data from the phase IIIb CLIPPER trial in Juvenile rheumatoid arthritis and Psoriatic arthritis (In adolescents, In children) presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top